U.S. markets closed
  • S&P 500

    4,063.04
    -89.06 (-2.14%)
     
  • Dow 30

    33,587.66
    -681.50 (-1.99%)
     
  • Nasdaq

    13,031.68
    -357.75 (-2.67%)
     
  • Russell 2000

    2,135.14
    -71.85 (-3.26%)
     
  • Crude Oil

    65.72
    +0.44 (+0.67%)
     
  • Gold

    1,815.90
    -20.20 (-1.10%)
     
  • Silver

    27.64
    -0.02 (-0.06%)
     
  • EUR/USD

    1.2076
    -0.0076 (-0.63%)
     
  • 10-Yr Bond

    1.6950
    +0.0710 (+4.37%)
     
  • GBP/USD

    1.4059
    -0.0085 (-0.60%)
     
  • USD/JPY

    109.6600
    +1.0400 (+0.96%)
     
  • BTC-USD

    54,564.75
    -2,026.54 (-3.58%)
     
  • CMC Crypto 200

    1,478.26
    -85.57 (-5.47%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

U.S. begins studying risk of allergic reactions to Moderna, Pfizer COVID-19 vaccines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

April 7 (Reuters) - The U.S. National Institutes of Health said on Wednesday it had begun a mid-stage study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna Inc and Pfizer Inc. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)